Treatment options for metastatic hormone-sensitive prostate cancer

Louise Kostos¹, Declan G Murphy²

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² Department of Urology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: declan.murphy@petermac.org.

PMID: 36075259
DOI: 10.1016/S1470-2045(22)00520-4

Comment

Treatment options for metastatic hormone-sensitive prostate cancer

Louise Kostos et al. Lancet Oncol. 2022 Oct.

. 2022 Oct;23(10):1234-1235.

doi: 10.1016/S1470-2045(22)00520-4. Epub 2022 Sep 5.

Authors

Louise Kostos¹, Declan G Murphy²

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² Department of Urology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: declan.murphy@petermac.org.

PMID: 36075259
DOI: 10.1016/S1470-2045(22)00520-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

LK reports reimbursement for speaker duties from Bayer. DGM reports reimbursement for speaker duties and advisory board activity for Janssen, Bayer, Astellas, Ipsen, AstraZeneca, and Device Technologies.

Comment on

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment options for metastatic hormone-sensitive prostate cancer

Affiliations

Treatment options for metastatic hormone-sensitive prostate cancer

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical